Advertisement

Topics

Akebia Therapeutics Announces Third Quarter 2017 Financial Results

16:05 EST 8 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
--Partner Mitsubishi Tanabe Pharma Corporation Initiates Phase 3 Development Program for Vadadustat in Japan-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative ther...

Other Sources for this Article

Akebia Therapeutics
John Garabo, 617-844-6130
Director, Corporate Communications
jgarabo@akebia.com

NEXT ARTICLE

More From BioPortfolio on "Akebia Therapeutics Announces Third Quarter 2017 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...